Are you a teenager with moderate to severe atopic dermatitis?

Amgen is conducting a Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of XXXXXXXXXXX in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #20210145

Share this post

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Call us, write us, or knock on our door.

Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.